Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Komal L JhaveriElgene LimRinath M JeselsohnCynthia X MaErika Paige HamiltonCynthia OsborneManali BhavePeter A KaufmanJ Thaddeus BeckLuis Manso SanchezRitesh ParajuliHwei-Chung WangJessica J TaoSeock-Ah ImKathleen K HarndenKan YonemoriAjay DhakalPatrick NevenPhilippe AftimosJean-Yves PiergaYen-Shen LuTimothy LarsonYolanda JerezKostandinos SiderasJoo Hyuk SohnSung-Bae KimCristina SauraAditya BardiaSarah L SammonsFrancesca BacchionYujia LiEunice YuenShawn T EstremVanessa Rodrik-OutmezguineBastien NguyenRoohi Ismail-KhanLillian M SmythMuralidhar BeeramPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2- ABC.